MLRagent

Qualifying SUPERs should appear close enough to the claim they qualify

DraftwarningFDA guidance · non-bindingRaised as a question — a person decides

Rule

A qualifying SUPER should appear close enough in time/position to the claim or risk statement it qualifies; otherwise a misleading impression of the product may result.

Check

Check the temporal proximity of each qualifying SUPER to the claim it modifies; flag SUPERs that appear well before or after the relevant claim.

Escalate when

When proximity is borderline and the audience's ability to connect the SUPER to the claim is unclear.

Where this comes from

Section III.C.2, Non-Print Promotion, Textual Elements · page 22. The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…ying phrase by acts or statements of the seller.” FDA has similar concerns. FDA assesses the temporal location of SUPERs within a broadcast ad or video when evaluating whether it is false or misleading. If claims must be qualified to avoid misleading the audience, we recommend that the qualifier be vocalized, presented through visual images, or placed in a prominent SUPER that runs concurrently with the claim. If SUPERs do not appear close enough to the claim or risk information requiring qualification, a misleading impression of the product may result. In addition, if qualifying information is complex and requires more than one line of text, we recommend that manufacturers use other means to convey this information. Other issues FDA considers important that manufacturers should keep in mind include the following: — SUPERs, if used, should be reasonably visible to a person under typical viewing conditions. — All SUPERs should be on screen long enough to allow …
Document
FDA guidance: Presenting Risk Information in Prescription Drug and Medical Device Promotion (see document)
Version
as retrieved — the publisher does not version this document; the fingerprint below identifies the exact file
Retrieved
2026-09-21 from www.fda.gov
Fingerprint
f5654ab082f6cd4408143f16…

FDA guidance describes the agency's current thinking. It is not binding law, and this rule is a recommendation, not an obligation.